Poolbeg expands POLB 001 into oncology
Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is…
January 17, 2023 - 3 minutes
CAR-T Cell Therapy: Revolutionizing Oncology One Step at a Time
The idea that our immune system can be rewired to fight cancer has resulted in huge expectations and an influx of investments into the immuno-oncology field. Following the market success of immune checkpoint inhibitors, more and more attention is turning to CAR-T cell therapy, with the first CAR-T therapy, Novartis’ Kymriah, approved in 2017.
With five CAR-T therapies on the global market already and over hundreds of clinical trials currently running, the field is now booming. Read on to keep up-to-date with the evolving CAR-T cell therapy market and ongoing research.
Show More
Editor's Picks for CAR-T
- A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
- Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer?
- From Big Pharma to Startup CEO: Lessons from Kymriah Developer Gaurav Shah
- Gene-Edited T Cell Therapy Players Battle Safety Doubts
- How European Startups Have Advanced Cancer T-Cell Therapy in 2020
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportLatest CAR-T Articles
Cartherics granted first patent in China
Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer,…
January 9, 2023 - 2 minutes
New biomarker for early prediction of response to CAR-T cell therapy
A MedUni Vienna research team in Austria has discovered a new highly potent biomarker for…
January 9, 2023 - 4 minutes
First CAR-T technology trial for patients with T-cell leukemia subtype authorized
The Spanish Agency of Medicines and Medical Products (AEMPS) has approved the CARxALL clinical trial…
December 22, 2022 - 4 minutes
Ebvallo approval ushers in off-the-shelf T-cell immunotherapies
Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU…
December 20, 2022 - 6 minutes
Sponsored
by Champions Oncology
Deciphering blood cancer complexity with multi-omics and patient-relevant disease models
A new case of blood cancer gets diagnosed approximately every three minutes in Western countries.…
December 5, 2022 - 7 minutes
Legend Biotech small cell lung cancer drug gets FDA ok for clinical development
Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared…
November 21, 2022 - 2 minutes
SOTIO reveal potential treatment for adults with solid tumors at SITC meeting
SOTIO Biotech has presented preclinical results of its BOXR T cell therapy platform and revealed…
November 10, 2022 - 4 minutes
Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma
The Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd (Cartherics) have entered into…
November 8, 2022 - 3 minutes
Spanish research institution to use Elicera Therapeutics’ iTANK platform
Elicera Therapeutics AB has entered a material transfer agreement with the Josep Carreras Leukaemia Research…
October 20, 2022 - 3 minutes
The biggest private biotech investments in September 2022
The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022,…
October 11, 2022 - 3 minutes
Mission Bio launches first commercial high-throughput cell therapy assay for measuring vector copy number
Mission Bio has announced the availability of the Tapestri VCN Assay, the first high-throughput commercial…
October 7, 2022 - 3 minutes
